News
All News
Publications
All PublicationsPharmTechPharmTech Europe
Multimedia
All VideosAsk the ExpertBehind The HeadlinesDrug Digest VideosDrug Solutions Podcast
Conferences
Conference CoverageConference Listing
More
Webcasts
Resources
ICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPartnersPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksState of the ScienceWhitepapers

Subscribe

  • News
  • Publications
  • Multimedia
  • Conferences
  • Webcasts
  • Resources
  • Subscribe
  • Analytics
    • Bio/Pharmaceutical Analysis Techniques
    • Laboratory Equipment and Instruments
  • Data and Artificial Intelligence
  • Dosage Forms
    • Solid/Semi-Solid Dosage
    • Specialty Dosage Drugs
    • Parenterals and Injectables
    • Inhalation Drugs
  • Drug Development
    • Intellectual Property and Patents
    • Process and Scaling
    • APIs and Excipients
    • Ingredients
    • Formulation and Drug Delivery
  • Manufacturing
    • Aseptic/Sterile Processing
    • Equipment
    • Process and Automation
    • Manufacturing, Parenterals and Injectables
    • Manufacturing, Biosimilars and Biobetters
    • Manufacturing, Inhalation Drugs
    • Manufacturing, Solid and Semi-Solid Dosage Drugs
    • Manufacturing, Cell Therapies
    • Manufacturing, Biologic Drugs
    • Supply Chain
    • Manufacturing, Gene Therapies
    • Packaging and Distribution
  • Outsourcing
    • Contract Research Services
    • Contract Analytical Services
    • Contract Development Services
    • Regulatory Consulting
    • Logistics and Distribution
    • Contract Manufacturing Services
  • Quality Systems
    • Ask the Expert
    • Quality Assurance/Quality Control
    • Regulatory Oversight and Compliance
Spotlight -
Analytics|
Dosage Forms|
Drug Development|
Manufacturing|
Outsourcing|
Quality Systems
Advertisement

Mitali Bhalme

Advertisement

Articles by Mitali Bhalme

Evaluating Impurities in Drugs (Part II of III)

ByPonnaiah Ravi,Kashyap R. Wadekar,S. Srinivasa Rao,E. Balasubrahmanyam,Mitali Bhalme,L. Sampath Kumar,K. Vigneshwar Reddy
March 1st 2012

In Part II of a three-part article, the authors examine impurities from chiral molecules, polymorphic contaminants, and genotoxic impurities.

Evaluating Impurities in Drugs (Part I of III)

ByKashyap R. Wadekar,S. Srinivasa Rao,E. Balasubrahmanyam,Mitali Bhalme,L. Sampath Kumar,K. Vigneshwar Reddy
February 1st 2012

In Part I of a three-part article, the authors discuss what constitutes an impurity and the potential sources of impurities in APIs and finished drug products.

Advertisement

Latest Updated Articles

  • Evaluating Impurities in Drugs (Part II of III)
    Evaluating Impurities in Drugs (Part II of III)

    Published: March 1st 2012 | Updated:

  • Evaluating Impurities in Drugs (Part I of III)
    Evaluating Impurities in Drugs (Part I of III)

    Published: February 1st 2012 | Updated:



Advertisement
Advertisement

Trending on Pharmaceutical Technology

1

CNPV Deep Dive: Perspectives on Accelerated FDA Review From the C-Suite to the Manufacturing Floor

2

Is Pharma Solving the Right Problem with its Data Transformation Efforts?

3

De-risking Biologic Development: Engineering Flexibility from Early Development to Launch

4

Multi-Compendial Compliance for Pharmaceutical Excipients–Part 1: A Practical Application of Specification Equivalence

5

Johnson & Johnson’s Tecvayli Combo Wins FDA National Priority Voucher

  • About Us
  • Advertise
  • Contact Us
  • Editorial Info
  • Editorial Advisory Board
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us